Top in dermatology: Therapies for basal cell carcinoma, molluscum contagiosum show promise
Early data from a phase 1/2 trial showed promising results for AIV001, AiViva Biopharma’s intradermal basal cell carcinoma treatment, according to a company press release.
“We are excited to have completed this safety study that is demonstrating excellent skin tolerability and a dose response,” Diane Tang-Liu, PhD, president and CEO of AiViva, said in the release.
It was the top story in dermatology last week.
Another top story reported positive results from a phase 3 trial in Japan that investigated a treatment for molluscum contagiosum. Torii Pharmaceutical, a partner of Verrica Pharmaceuticals, signed an exclusive licensing agreement for the development and commercialization of TO-208 (cantharidin) in Japan. The treatment is also known as VP-102 and marketed as Ycanth in the United States.
Read these and more top stories in dermatology below:
Phase 1/2 trial of AiViva Biopharma’s intradermal basal cell carcinoma treatment complete
AiViva Biopharma has completed a phase 1/2 trial of AIV001, a nonsurgical treatment for basal cell carcinoma, the company announced in a press release. Read more.
Japanese trial shows TO-208 efficacious in molluscum contagiosum
Torii Pharmaceutical Co. Ltd. has reported positive top-line results for a phase 3 trial evaluating TO-208 for the treatment of molluscum contagiosum in Japan, Verrica Pharmaceuticals announced in a press release. Read more.
Aesthetic approvals top Healio Dermatology FDA news in 2023
The FDA approved multiple products for dermatologic indications this year. Read more.
Sanofi anticipates growing portfolio in coming years
Sanofi has released updates and insight into its innovation pipeline and new growth drivers, the company announced in a press release. Read more.
Approval of triple-combination gel tops most read Healio acne news of 2023
The FDA’s approval of IDP-126 was the most read Healio acne story this year, followed by coverage of a study finding IDP-126 improves patients’ quality of life compared to vehicle. News regarding the efficacy of M-PDT and clascoterone cream, as well as an update to the FDA’s iPledge recommendations, rounded out 2023’s important acne updates. Read more.